nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

18.11.2019 | Original Article

From metabolic connectivity to molecular connectivity: application to dopaminergic pathways

verfasst von: Antoine Verger, Tatiana Horowitz, Mohammad B. Chawki, Alexandre Eusebio, Manon Bordonne, Jean-Philippe Azulay, Nadine Girard, Eric Guedj

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This study aims to reveal the feasibility and potential of molecular connectivity based on neurotransmission in comparison with the metabolic connectivity with an application to dopaminergic pathways. For this purpose, we propose to compare the neurotransmission connectivity findings using ¹²³I-FP-CIT SPECT and ¹⁸F-FDOPA PET with the metabolic connectivity findings using ¹⁸F-FDG PET.

Methods

¹⁸F-FDG PET and ¹²³I-FP-CIT SPECT images from 47 subjects and ¹⁸F-FDOPA PET images from 177 subjects, who had no neurological or psychiatric disorders, were studied. Interregional correlation analyses were performed at the group level to determine the midbrain’s connectivity via glucose metabolic rate using ¹⁸F-FDG PET and via dopaminergic binding potential using ¹²³I-FP-CIT SPECT and ¹⁸F-FDOPA PET. SPM-T maps of each radiotracer were generated, and masks used to highlight the significant differences obtained among the imaging modalities and targets.

Results

The three dopaminergic pathways (i.e., nigrostriatal, mesolimbic, and mesocortical) were identified by ¹⁸F-FDG PET (1599 voxels, with a T_max value of 12.6), ¹²³I-FP-CIT SPECT (1120 voxels, with T_max value of 5.1), and ¹⁸F-FDOPA PET (6054 voxels, with T_max value of 11.7) for a T voxel threshold of 5.10, 2.80, and 5.10, respectively. Using the same T voxel threshold of 5.10, ¹⁸F-FDOPA PET showed more specific findings than ¹⁸F-FDG PET with less voxels identified outside these pathways (− 9323 voxels), whereas no significant voxels were obtained with ¹²³I-FP-CIT SPECT at this threshold.

Conclusion

The present study illustrates the feasibility and interest in using molecular connectivity with ¹⁸F-FDOPA PET for dopaminergic pathways. Such analyses could be applied to specific diseases involving the dopaminergic system.

Horwitz B, Duara R, Rapoport SI. Intercorrelations of glucose metabolic rates between brain regions: application to healthy males in a state of reduced sensory input. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1984;4:484–99.

Metter EJ, Riege WH, Kameyama M, Kuhl DE, Phelps ME. Cerebral metabolic relationships for selected brain regions in Alzheimer’s, Huntington’s, and Parkinson’s diseases. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1984;4:500–6.

Clark CM, Stoessl AJ. Glucose use correlations: a matter of inference. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 1986;6:511–2.

Yakushev I, Drzezga A, Habeck C. Metabolic connectivity: methods and applications. Curr Opin Neurol. 2017;30:677–85.PubMed

Verger A, Klesse E, Chawki MB, Witjas T, Azulay J-P, Eusebio A, et al. Brain PET substrate of impulse control disorders in Parkinson’s disease: a metabolic connectivity study. Hum Brain Mapp. 2018;39:3178–86.PubMed

The REMPET Study Group Sittig-Wiegand Elisabeth f Depboylu Candan f Reetz Kathrin l Overeem Sebastiaan m Pijpers Angelique m Reesink Fransje E. b van Laar Teus b Teune Laura K. b Höffken Helmut n Luster Marcus n Timmermann Lars f Kesper Karl o Adriaanse Sofie M. p Booij Jan p Sambuceti Gianmario d Girtler Nicola a, Arnaldi D, Meles SK, Giuliani A, Morbelli S, Renken RJ, et al. Brain glucose metabolism heterogeneity in idiopathic REM Sleep behavior disorder and in parkinson’s disease. J Park Dis. 2019;9:229–39.

Lee DS, Kang H, Kim H, Park H, Oh JS, Lee JS, et al. Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging. 2008;35:1681–91.PubMed

Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, van Berckel BNM, et al. Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging. 2012;33:2533–50.PubMed

Gardner A, Åstrand D, Öberg J, Jacobsson H, Jonsson C, Larsson S, et al. Towards mapping the brain connectome in depression: functional connectivity by perfusion SPECT. Psychiatry Res Neuroimaging. 2014;223:171–7.

10.

Hahn A, Lanzenberger R, Kasper S. Making Sense of Connectivity. Int J Neuropsychopharmacol. 2019;22:194–207.PubMed

11.

Tuominen L, Nummenmaa L, Keltikangas-Järvinen L, Raitakari O, Hietala J. Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems: mapping neurotransmitter networks with PET. Hum Brain Mapp. 2014;35:1875–84.PubMed

12.

Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir HL, James GM, Hahn A, et al. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Hum Brain Mapp. 2017;38:792–802.PubMed

13.

Veronese M, Moro L, Arcolin M, Dipasquale O, Rizzo G, Expert P, et al. Covariance statistics and network analysis of brain PET imaging studies. Sci Rep. 2019;9:2496.PubMedPubMedCentral

14.

Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science. 1958;127:471.PubMed

15.

Cooper DC. The significance of action potential bursting in the brain reward circuit. Neurochem Int. 2002;41:333–40.PubMed

16.

Floresco SB, Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berl). 2006;188:567–85.PubMed

17.

Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2010;35:4–26.

18.

Fuxe K, Agnati LF, Kalia M, Goldstein M, Andersson K, Härfstrand A. Dopaminergic systems in the brain and pituitary. Dopaminergic Syst [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 1985 [cited 2019 Apr 8]. p. 11–25. Available from: http://www.springerlink.com/index/10.1007/978-3-642-69948-1_2 SMASH

19.

Bloom FE, Björklund A, Hökfelt T. The primate nervous system. Part I. Amsterdam. New York: Elsevier; 1997.

20.

Dunnett SB. Dopamine [Internet]. Amsterdam; Boston: Elsevier; 2005 [cited 2019 Apr 8]. Available from: http://www.sciencedirect.com/science/book/9780444517784

21.

Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci 1962. 1964;3:523–30.PubMed

22.

Andén N-E, Dahlström A, Fuxe K, Larsson K. Further evidence for the presence of nigro-neostriatal dopamine neurons in the rat: nigro-neostriatal dopamine neurons. Am J Anat. 1965;116:329–33.PubMed

23.

Hu Z, Cooper M, Crockett DP, Zhou R. Differentiation of the midbrain dopaminergic pathways during mouse development. J Comp Neurol. 2004;476:301–11.PubMed

24.

Gerfen CR. Functional neuroanatomy of dopamine in the striatum. In: Iversen L, Iversen S, Dunnett S, Bjorklund A, editors. Dopamine Handb [Internet]. Oxford University Press; 2009 [cited 2019 Apr 8]. p. 11–21. Available from: http://www.oxfordscholarship.com/view/10.1093/acprof:oso/9780195373035.001.0001/acprof-9780195373035-chapter-2 SMASH

25.

Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. 2nd ed. New York: McGraw-Hill Medical; 2009.

26.

Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci. 1999;354:1155–63.PubMedPubMedCentral

27.

Eusebio A, Azulay J-P, Ceccaldi M, Girard N, Mundler O, Guedj E. Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. Eur J Nucl Med Mol Imaging. 2012;39:1778–83.PubMed

28.

Darcourt J, Schiazza A, Sapin N, Dufour M, Ouvrier MJ, Benisvy D, et al. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of. 2014;58:355–65.

29.

Toch S-R, Poussier S, Micard E, Bertaux M, Van Der Gucht A, Chevalier E, et al. Physiological whole-brain distribution of [18F]FDOPA uptake index in relation to age and gender: results from a voxel-based semi-quantitative analysis. Mol Imaging Biol [Internet]. 2018 [cited 2019 Mar 11]; Available from: http://link.springer.com/10.1007/s11307-018-1256-1 SMASH

30.

Hoffman JM, Melega WP, Hawk TC, Grafton SC, Luxen A, Mahoney DK, et al. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. J Nucl Med Off Publ Soc Nucl Med. 1992;33:1472–7.

31.

Verger A, Roman S, Chaudat R-M, Felician O, Ceccaldi M, Didic M, et al. Changes of metabolism and functional connectivity in late-onset deafness: evidence from cerebral 18F-FDG-PET. Hear Res. 2017;353:8–16.PubMed

32.

Kas A, Payoux P, Habert M-O, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med. 2007;48:1459–67.PubMed

33.

Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med Off Publ Soc Nucl Med. 2009;50:893–9.

34.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15:273–89.PubMed

35.

Lieberman MD, Cunningham WA. Type I and type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci. 2009;4:423–8.PubMedPubMedCentral

36.

Lindvall O, Björklund A. Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway. Brain Res. 1979;172:169–73.PubMed

37.

Sanchez-Gonzalez MA. The primate thalamus is a key target for brain dopamine. J Neurosci. 2005;25:6076–83.PubMedPubMedCentral

38.

Gardner EL, Ashby CR. Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology. Neurosci Biobehav Rev. 2000;24:115–8.PubMed

39.

Hosp JA, Luft AR. Dopaminergic meso-cortical projections to M1: role in motor learning and motor cortex plasticity. Front Neurol [Internet]. 2013 [cited 2019 Apr 8];4. Available from: http://journal.frontiersin.org/article/10.3389/fneur.2013.00145/abstract SMASH

40.

Meck WH. Neuroanatomical localization of an internal clock: a functional link between mesolimbic, nigrostriatal, and mesocortical dopaminergic systems. Brain Res. 2006;1109:93–107.PubMed

41.

Bär K-J, de la Cruz F, Schumann A, Koehler S, Sauer H, Critchley H, et al. Functional connectivity and network analysis of midbrain and brainstem nuclei. NeuroImage. 2016;134:53–63.PubMed

42.

Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: a lateralized monoaminergic frontostriatal disconnection syndrome? Parkinsonism Relat Disord. 2016;30:62–6.PubMed

43.

Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193–207.PubMed

44.

Cervenka S, Varrone A, Fransén E, Halldin C, Farde L. PET studies of D2-receptor binding in striatal and extrastriatal brain regions: biochemical support in vivo for separate dopaminergic systems in humans. Synap N Y N. 2010;64:478–85.

45.

Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. NeuroImage Clin. 2017;14:734–40.PubMedPubMedCentral

46.

Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien L-K, et al. Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci Off J Soc Neurosci. 2010;30:14482–9.

Titel: From metabolic connectivity to molecular connectivity: application to dopaminergic pathways
verfasst von: Antoine Verger
Tatiana Horowitz
Mohammad B. Chawki
Alexandre Eusebio
Manon Bordonne
Jean-Philippe Azulay
Nadine Girard
Eric Guedj
Publikationsdatum: 18.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04574-3

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET”

Publisher Correction: Artificial intelligence and radiomics in nuclear medicine: potentials and challenges

The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948

Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise